1130 related articles for article (PubMed ID: 35263534)
21. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
[TBL] [Abstract][Full Text] [Related]
22. A Bivalent Omicron-Containing Booster Vaccine against Covid-19.
Chalkias S; Harper C; Vrbicky K; Walsh SR; Essink B; Brosz A; McGhee N; Tomassini JE; Chen X; Chang Y; Sutherland A; Montefiori DC; Girard B; Edwards DK; Feng J; Zhou H; Baden LR; Miller JM; Das R
N Engl J Med; 2022 Oct; 387(14):1279-1291. PubMed ID: 36112399
[TBL] [Abstract][Full Text] [Related]
23. Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar.
Chemaitelly H; Ayoub HH; AlMukdad S; Coyle P; Tang P; Yassine HM; Al-Khatib HA; Smatti MK; Hasan MR; Al-Kanaani Z; Al-Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul-Rahim HF; Nasrallah GK; Al-Kuwari MG; Butt AA; Al-Romaihi HE; Al-Thani MH; Al-Khal A; Bertollini R; Abu-Raddad LJ
Nat Commun; 2022 Jun; 13(1):3082. PubMed ID: 35654888
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness of primary series and booster vaccination against SARS-CoV-2 infection and hospitalisation among adolescents aged 12-17 years in Singapore: a national cohort study.
Chiew CJ; Premikha M; Chong CY; Wei WE; Ong B; Lye DC; Heng D; Lee VJ; Tan KB
Lancet Infect Dis; 2023 Feb; 23(2):177-182. PubMed ID: 36182678
[TBL] [Abstract][Full Text] [Related]
25. Comparative effectiveness of heterologous third dose vaccine schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analyses.
Andersson NW; Thiesson EM; Baum U; Pihlström N; Starrfelt J; Faksová K; Poukka E; Lund LC; Hansen CH; Aakjær M; Kjær J; Cohet C; Goossens M; Andersen M; Hallas J; Meijerink H; Ljung R; Hviid A
BMJ; 2023 Jul; 382():e074325. PubMed ID: 37487623
[TBL] [Abstract][Full Text] [Related]
26. Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel.
Spitzer A; Angel Y; Marudi O; Zeltser D; Saiag E; Goldshmidt H; Goldiner I; Stark M; Halutz O; Gamzu R; Slobodkin M; Amrami N; Feigin E; Elbaz M; Furman M; Bronstein Y; Chikly A; Eshkol A; Furer V; Mayer T; Meijer S; Melloul A; Mizrahi M; Yakubovsky M; Rosenberg D; Safir A; Spitzer L; Taleb E; Elkayam O; Silberman A; Eviatar T; Elalouf O; Levinson T; Pozyuchenko K; Itzhaki-Alfia A; Sprecher E; Ben-Ami R; Henig O
JAMA; 2022 Jan; 327(4):341-349. PubMed ID: 35006256
[TBL] [Abstract][Full Text] [Related]
27. Coronavirus Disease 19 (COVID-19) Vaccine Effectiveness Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Delta-Dominant and Omicron-Dominant Periods in Japan: A Multicenter Prospective Case-control Study (Factors Associated with SARS-CoV-2 Infection and the Effectiveness of COVID-19 Vaccines Study).
Arashiro T; Arima Y; Muraoka H; Sato A; Oba K; Uehara Y; Arioka H; Yanai H; Kuramochi J; Ihara G; Chubachi K; Yanagisawa N; Nagura Y; Kato Y; Ueda A; Numata A; Kato H; Ishii K; Ooki T; Oka H; Nishida Y; Stucky A; Smith C; Hibberd M; Ariyoshi K; Suzuki M
Clin Infect Dis; 2023 Feb; 76(3):e108-e115. PubMed ID: 35918782
[TBL] [Abstract][Full Text] [Related]
28. Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study.
Chemaitelly H; Ayoub HH; Tang P; Coyle P; Yassine HM; Al Thani AA; Al-Khatib HA; Hasan MR; Al-Kanaani Z; Al-Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul-Rahim HF; Nasrallah GK; Al-Kuwari MG; Butt AA; Al-Romaihi HE; Al-Thani MH; Al-Khal A; Bertollini R; Faust JS; Abu-Raddad LJ
Lancet Infect Dis; 2023 Jul; 23(7):816-827. PubMed ID: 36913963
[TBL] [Abstract][Full Text] [Related]
29. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.
Menni C; May A; Polidori L; Louca P; Wolf J; Capdevila J; Hu C; Ourselin S; Steves CJ; Valdes AM; Spector TD
Lancet Infect Dis; 2022 Jul; 22(7):1002-1010. PubMed ID: 35405090
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of BNT162b2 mRNA vaccine third doses and previous infection in protecting against SARS-CoV-2 infections during the Delta and Omicron variant waves; the UK SIREN cohort study September 2021 to February 2022.
Hall VJ; Insalata F; Foulkes S; Kirwan P; Sparkes D; Atti A; Cole M; de Lacy E; Price L; Corrigan D; Brown CS; Islam J; Charlett A; Hopkins S;
J Infect; 2024 Jan; 88(1):30-40. PubMed ID: 37926119
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study.
Tartof SY; Slezak JM; Puzniak L; Hong V; Frankland TB; Ackerson BK; Xie F; Takhar H; Ogun OA; Simmons S; Zamparo JM; Valluri SR; Jodar L; McLaughlin JM
Lancet Respir Med; 2023 Dec; 11(12):1089-1100. PubMed ID: 37898148
[TBL] [Abstract][Full Text] [Related]
32. Vaccine Effectiveness of 3 Versus 2 Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccines in a High-Risk National Population.
Butt AA; Talisa VB; Yan P; Shaikh OS; Omer SB; Mayr FB
Clin Infect Dis; 2022 Aug; 75(1):e579-e584. PubMed ID: 35245940
[TBL] [Abstract][Full Text] [Related]
33. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.
Powell AA; Kirsebom F; Stowe J; Ramsay ME; Lopez-Bernal J; Andrews N; Ladhani SN
Lancet Infect Dis; 2023 Apr; 23(4):435-444. PubMed ID: 36436536
[TBL] [Abstract][Full Text] [Related]
34. Effects of COVID-19 vaccination and previous SARS-CoV-2 infection on omicron infection and severe outcomes in children under 12 years of age in the USA: an observational cohort study.
Lin DY; Xu Y; Gu Y; Zeng D; Wheeler B; Young H; Moore Z; Sunny SK
Lancet Infect Dis; 2023 Nov; 23(11):1257-1265. PubMed ID: 37336222
[TBL] [Abstract][Full Text] [Related]
35. Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial.
Lee IT; Cosgrove CA; Moore P; Bethune C; Nally R; Bula M; Kalra PA; Clark R; Dargan PI; Boffito M; Sheridan R; Moran E; Darton TC; Burns F; Saralaya D; Duncan CJA; Lillie PJ; San Francisco Ramos A; Galiza EP; Heath PT; Girard B; Parker C; Rust D; Mehta S; de Windt E; Sutherland A; Tomassini JE; Dutko FJ; Chalkias S; Deng W; Chen X; Feng J; Tracy L; Zhou H; Miller JM; Das R;
Lancet Infect Dis; 2023 Sep; 23(9):1007-1019. PubMed ID: 37348519
[TBL] [Abstract][Full Text] [Related]
36. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar.
Tang P; Hasan MR; Chemaitelly H; Yassine HM; Benslimane FM; Al Khatib HA; AlMukdad S; Coyle P; Ayoub HH; Al Kanaani Z; Al Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul Rahim HF; Nasrallah GK; Al Kuwari MG; Al Romaihi HE; Butt AA; Al-Thani MH; Al Khal A; Bertollini R; Abu-Raddad LJ
Nat Med; 2021 Dec; 27(12):2136-2143. PubMed ID: 34728831
[TBL] [Abstract][Full Text] [Related]
37. Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France.
Tamandjou Tchuem CR; Auvigne V; Vaux S; Montagnat C; Paireau J; Monnier Besnard S; Gabet A; Benhajkassen N; Le Strat Y; Parent Du Chatelet I; Levy-Bruhl D
Vaccine; 2023 Mar; 41(13):2280-2288. PubMed ID: 36870880
[TBL] [Abstract][Full Text] [Related]
38. Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance.
Fleming-Dutra KE; Britton A; Shang N; Derado G; Link-Gelles R; Accorsi EK; Smith ZR; Miller J; Verani JR; Schrag SJ
JAMA; 2022 Jun; 327(22):2210-2219. PubMed ID: 35560036
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
Thompson MG; Natarajan K; Irving SA; Rowley EA; Griggs EP; Gaglani M; Klein NP; Grannis SJ; DeSilva MB; Stenehjem E; Reese SE; Dickerson M; Naleway AL; Han J; Konatham D; McEvoy C; Rao S; Dixon BE; Dascomb K; Lewis N; Levy ME; Patel P; Liao IC; Kharbanda AB; Barron MA; Fadel WF; Grisel N; Goddard K; Yang DH; Wondimu MH; Murthy K; Valvi NR; Arndorfer J; Fireman B; Dunne MM; Embi P; Azziz-Baumgartner E; Zerbo O; Bozio CH; Reynolds S; Ferdinands J; Williams J; Link-Gelles R; Schrag SJ; Verani JR; Ball S; Ong TC
MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):139-145. PubMed ID: 35085224
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant - United States, February 14-March 27, 2022.
Prasad N; Derado G; Nanduri SA; Reses HE; Dubendris H; Wong E; Soe MM; Li Q; Dollard P; Bagchi S; Edwards J; Shang N; Budnitz D; Bell J; Verani JR; Benin A; Link-Gelles R; Jernigan J; Pilishvili T
MMWR Morb Mortal Wkly Rep; 2022 May; 71(18):633-637. PubMed ID: 35511708
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
